Biohaven Pharmaceutical Holding Total Assets 2016-2022 | BHVN

Biohaven Pharmaceutical Holding total assets from 2016 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Biohaven Pharmaceutical Holding total assets for the quarter ending June 30, 2022 were $1.386B, a 63.88% increase year-over-year.
  • Biohaven Pharmaceutical Holding total assets for 2021 were $1.077B, a 56.81% increase from 2020.
  • Biohaven Pharmaceutical Holding total assets for 2020 were $0.687B, a 99.55% increase from 2019.
  • Biohaven Pharmaceutical Holding total assets for 2019 were $0.344B, a 18.71% increase from 2018.
Biohaven Pharmaceutical Holding Annual Total Assets
(Millions of US $)
2021 $1,077
2020 $687
2019 $344
2018 $290
2017 $147
2016 $27
2015 $2
Biohaven Pharmaceutical Holding Quarterly Total Assets
(Millions of US $)
2022-06-30 $1,386
2022-03-31 $1,372
2021-12-31 $1,077
2021-09-30 $1,131
2021-06-30 $846
2021-03-31 $1,003
2020-12-31 $687
2020-09-30 $782
2020-06-30 $424
2020-03-31 $533
2019-12-31 $0
2019-09-30 $439
2019-06-30 $491
2019-03-31 $245
2018-12-31 $290
2018-09-30 $195
2018-06-30 $239
2018-03-31 $126
2017-12-31 $147
2017-09-30 $185
2017-06-30 $214
2017-03-31 $60
2016-12-31 $27
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.873B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.984B 9.16
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
QIAGEN (QGEN) Netherlands $9.383B 15.71
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Arcus Biosciences (RCUS) United States $1.819B 35.51
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
Emergent Biosolutions (EBS) United States $1.040B 6.03
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Enzo Biochem (ENZ) United States $0.105B 0.00
Gelesis Holdings (GLS) United States $0.081B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00